Table of Contents Author Guidelines Submit a Manuscript
Journal of Biomedicine and Biotechnology
Volume 2010, Article ID 268436, 8 pages
http://dx.doi.org/10.1155/2010/268436
Review Article

Cytokines and Chemokines in Neuropsychiatric Syndromes of Systemic Lupus Erythematosus

1Institute of Rheumatology, Tokyo Women’s Medical University, Tokyo 162-0054, Japan
2Minami-Otsuka Institute of Technology, Minami-Otsuka Clinic, Tokyo 170-0005, Japan

Received 9 February 2010; Accepted 21 May 2010

Academic Editor: Brian Poole

Copyright © 2010 Hiroshi Okamoto et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. “The American College of Rheumatology nomenclature and case definitions for neuropsychiatric lupus syndromes. ACR Ad Hoc Committee on Neuropsychiatric Lupus Nomenclature,” Arthritis and Rheumatism, vol. 42, no. 4, pp. 599–608, 1999. View at Publisher · View at Google Scholar · View at Scopus
  2. B. Bresnihan, “CNS lupus,” Clinics in Rheumatic Diseases, vol. 8, no. 1, pp. 183–195, 1982. View at Google Scholar · View at Scopus
  3. R. L. Brey, S. L. Holliday, A. R. Saklad et al., “Neuropsychiatric syndromes in lupus: prevalence using standardized definitions,” Neurology, vol. 58, no. 8, pp. 1214–1220, 2002. View at Google Scholar · View at Scopus
  4. H. Ainiala, J. Loukkola, J. Peltola, M. Korpela, and A. Hietaharju, “The prevalence of neuropsychiatric syndromes in systemic lupus erythematosus,” Neurology, vol. 57, no. 3, pp. 496–500, 2001. View at Google Scholar · View at Scopus
  5. E. Trysberg, H. Carlsten, and A. Tarkowski, “Intrathecal cytokines in systemic lupus erythematosus with central nervous system involvement,” Lupus, vol. 9, no. 7, pp. 498–503, 2000. View at Google Scholar · View at Scopus
  6. E. Svenungsson, M. Andersson, L. Brundin et al., “Increased levels of proinflammatory cytokines and nitric oxide metabolites in neuropsychiatric lupus erythematosus,” Annals of the Rheumatic Diseases, vol. 60, no. 4, pp. 372–379, 2001. View at Publisher · View at Google Scholar · View at Scopus
  7. N. Iikuni, H. Okamoto, T. Yoshio et al., “Raised monocyte chemotactic protein-1 (MCP-1)/CCL2 in cerebrospinal fluid of patients with neuropsychiatric lupus,” Annals of the Rheumatic Diseases, vol. 65, no. 2, pp. 253–256, 2006. View at Publisher · View at Google Scholar · View at Scopus
  8. H. Okamoto, N. Iikuni, S. Kamitsuji, T. Yoshio, S. Minota, and N. Kamatani, “IP-10/MCP-1 ratio in CSF is an useful diagnostic marker of neuropsychiatric lupus patients,” Rheumatology, vol. 45, no. 2, pp. 232–234, 2006. View at Publisher · View at Google Scholar · View at Scopus
  9. H. Okamoto, Y. Katsumata, K. Nishimura, and N. Kamatani, “Interferon-inducible protein 10/CXCL10 is increased in the cerebrospinal fluid of patients with central nervous system lupus,” Arthritis and Rheumatism, vol. 50, no. 11, pp. 3731–3732, 2004. View at Publisher · View at Google Scholar · View at Scopus
  10. M. Aringer, W. B. Graninger, G. Steiner, and J. S. Smolen, “Safety and efficacy of tumor necrosis factor α blockade in systemic lupus erythematosus: an open-label study,” Arthritis and Rheumatism, vol. 50, no. 10, pp. 3161–3169, 2004. View at Publisher · View at Google Scholar · View at Scopus
  11. A. Rahman and D. A. Isenberg, “Systemic lupus erythematosus,” New England Journal of Medicine, vol. 358, no. 9, pp. 929–939, 2008. View at Publisher · View at Google Scholar · View at Scopus
  12. J. Alcocer-Varela, D. Aleman-Hoey, and D. Alarcon-Segovia, “Interleukin-1 and interleukin-6 activities are increased in the cerebrospinal fluid of patients with CNS lupus erythematosus and correlate with local late T-cell activation markers,” Lupus, vol. 1, no. 2, pp. 111–117, 1992. View at Google Scholar · View at Scopus
  13. R. Gilad, Y. Lampl, Y. Eshel, V. Barak, and I. Sarova-Pinhas, “Cerebrospinal fluid soluble interleukin-2 receptor in cerebral lupus,” British Journal of Rheumatology, vol. 36, no. 2, pp. 190–193, 1997. View at Google Scholar · View at Scopus
  14. A. Jönsen, A. A. Bengtsson, O. Nived et al., “The heterogeneity of neuropsychiatric systemic lupus erythematosus is reflected in lack of association with cerebrospinal fluid cytokine profiles,” Lupus, vol. 12, no. 11, pp. 846–850, 2003. View at Publisher · View at Google Scholar · View at Scopus
  15. L. J. Jara, L. Irigoyen, M. J. De Ortiz, B. Zazueta, G. Bravo, and L. R. Espinoza, “Prolactin and interleukin-6 in neuropsychiatric lupus erythematosus,” Clinical Rheumatology, vol. 17, no. 2, pp. 110–114, 1998. View at Publisher · View at Google Scholar · View at Scopus
  16. S. Hirohata and T. Miyamoto, “Elevated levels of interleukin-6 in cerebrospinal fluid from patients with systemic lupus erythematosus and central nervous system involvement,” Arthritis and Rheumatism, vol. 33, no. 5, pp. 644–649, 1990. View at Publisher · View at Google Scholar · View at Scopus
  17. S. Hirohata and K. Hayakawa, “Enhanced interleukin-6 messenger RNA expression by neuronal cells in a patient with neuropsychiatric systemic lupus erythematosus,” Arthritis and Rheumatism, vol. 42, no. 12, pp. 2729–2730, 1999. View at Publisher · View at Google Scholar · View at Scopus
  18. C.-Y. Tsai, T.-H. Wu, S.-T. Tsai et al., “Cerebrospinal fluid interleukin-6, prostaglandin E2 and autoantibodies in patients with neuropsychiatric systemic lupus erythematosus and central nervous system infections,” Scandinavian Journal of Rheumatology, vol. 23, no. 2, pp. 57–63, 1994. View at Google Scholar · View at Scopus
  19. E. Trysberg, H. Carlsten, and A. Tarkowski, “Intrathecal cytokines in systemic lupus erythematosus with central nervous system involvement,” Lupus, vol. 9, no. 7, pp. 498–503, 2000. View at Google Scholar · View at Scopus
  20. R. Dellalibera-Joviliano, M. L. Dos Reis, F. D. Q. Cunha, and E. A. Donadi, “Kinins and cytokines in plasma and cerebrospinal fluid of patients with neuropsychiatric lupus,” Journal of Rheumatology, vol. 30, no. 3, pp. 485–492, 2003. View at Google Scholar · View at Scopus
  21. H. Fragoso-Loyo, Y. Richaud-Patin, A. Orozco-Narváez et al., “Interleukin-6 and chemokines in the neuropsychiatric manifestations of systemic lupus erythematosus,” Arthritis and Rheumatism, vol. 56, no. 4, pp. 1242–1250, 2007. View at Publisher · View at Google Scholar · View at Scopus
  22. D. M. Santer, T. Yoshio, S. Minota, T. Möller, and K. B. Elkon, “Potent induction of IFN-alpha and chemokines by autoantibodies in the cerebrospinal fluid of patients with neuropsychiatric lupus,” Journal of Immunology, vol. 182, no. 2, pp. 1192–1201, 2009. View at Google Scholar · View at Scopus
  23. R. Gilad, Y. Lampl, Y. Eshel, V. Barak, and I. Sarova-Pinhas, “Cerebrospinal fluid soluble interleukin-2 receptor in cerebral lupus,” British Journal of Rheumatology, vol. 36, no. 2, pp. 190–193, 1997. View at Google Scholar · View at Scopus
  24. J. B. Winfield, M. Shaw, L. M. Silverman et al., “Intrathecal IgG synthesis and blood-brain barrier impairment in patients with systemic lupus erythematosus and central nervous system dysfunction,” American Journal of Medicine, vol. 74, no. 5, pp. 837–844, 1983. View at Google Scholar · View at Scopus
  25. S. Shiozawa, Y. Kuroki, M. Kim, S. Hirohata, and T. Ogino, “Interferon-alpha in lupus psychosis,” Arthritis and Rheumatism, vol. 35, no. 4, pp. 417–422, 1992. View at Publisher · View at Google Scholar · View at Scopus
  26. S. Hirohata, Y. Kanai, A. Mitsuo, Y. Tokano, and H. Hashimoto, “Accuracy of cerebrospinal fluid IL-6 testing for diagnosis of lupus psychosis. A multicenter retrospective study. NPSLE Research Subcommittee,” Clinical Rheumatology, vol. 28, no. 11, pp. 1319–1323, 2009. View at Publisher · View at Google Scholar · View at Scopus
  27. A. George-Chandy, E. Trysberg, and K. Eriksson, “Raised intrathecal levels of APRIL and BAFF in patients with systemic lupus erythematosus: relationship to neuropsychiatric symptoms,” Arthritis Research and Therapy, vol. 10, no. 4, article R97, 2008. View at Publisher · View at Google Scholar · View at Scopus
  28. Y. Katsumata, M. Harigai, Y. Kawaguchi et al., “Diagnostic reliability of cerebral spinal fluid tests for acute confusional state (delirium) in patients with systemic lupus erythematosus: interleukin 6 (IL-6), IL-8, interferon-α, IgG index, and Q-albumin,” Journal of Rheumatology, vol. 34, no. 10, pp. 2010–2017, 2007. View at Google Scholar · View at Scopus
  29. T. Yoshio, S. Yamazaki, H. Okamoto et al., “IgG anti-NR2 glutamate receptor antibodies (anti-NR2) from patients with systemic lupus erythematosus (SLE) as causative auto-antibodies of damage to the blood-brain barrier (BBB),” in Proceedings of the ACR Annual Scientific Meeting, 2009.
  30. I. F. Charo and R. M. Ransohoff, “Mechanisms of disease: the many roles of chemokines and chemokine receptors in inflammation,” New England Journal of Medicine, vol. 354, no. 6, pp. 610–621, 2006. View at Publisher · View at Google Scholar · View at Scopus
  31. T. Iwamoto, H. Okamoto, Y. Toyama, and S. Momohara, “Molecular aspects of rheumatoid arthritis: chemokines in the joints of patients,” FEBS Journal, vol. 275, no. 18, pp. 4448–4455, 2008. View at Publisher · View at Google Scholar · View at Scopus
  32. A. D. Luster, “Mechanisms of disease: chemokines—chemotactic cytokines that mediate inflammation,” New England Journal of Medicine, vol. 338, no. 7, pp. 436–445, 1998. View at Publisher · View at Google Scholar · View at Scopus
  33. G. S. Kelner, J. Kennedy, K. B. Bacon et al., “Lymphotactin: a cytokine that represents a new class of chemokine,” Science, vol. 266, no. 5189, pp. 1395–1399, 1994. View at Google Scholar · View at Scopus
  34. J. F. Bazan, K. B. Bacon, G. Hardiman et al., “A new class of membrane-bound chemokine with a CX3C motif,” Nature, vol. 385, no. 6617, pp. 640–642, 1997. View at Publisher · View at Google Scholar · View at Scopus
  35. A. Zlotnik and O. Yoshie, “Chemokines: a new classification system and their role in immunity,” Immunity, vol. 12, no. 2, pp. 121–127, 2000. View at Google Scholar · View at Scopus
  36. K. Bacon, M. Baggiolini, H. Broxmeyer et al., “Chemokine/chemokine receptor nomenclature,” Journal of Interferon & Cytokine Research, vol. 22, pp. 1067–1068, 2002. View at Google Scholar
  37. P. Loetscher, M. Seitz, I. Clark-Lewis, M. Baggiolini, and B. Moser, “Monocyte chemotactic proteins MCP-1, MCP-2, and MCP-3 are major attractants for human CD4+ and CD8+ T lymphocytes,” FASEB Journal, vol. 8, no. 13, pp. 1055–1060, 1994. View at Google Scholar · View at Scopus
  38. T. J. Schall, K. Bacon, K. J. Toy, and D. V. Goeddel, “Selective attraction of monocytes and T lymphocytes of the memory phenotype by cytokine RANTES,” Nature, vol. 347, no. 6294, pp. 669–671, 1990. View at Publisher · View at Google Scholar · View at Scopus
  39. M. P. M. Vierboom, P. J. Zavodny, C.-C. Chou et al., “Inhibition of the development of collagen-induced arthritis in rhesus monkeys by a small molecular weight antagonist of CCR5,” Arthritis and Rheumatism, vol. 52, no. 2, pp. 627–636, 2005. View at Publisher · View at Google Scholar · View at Scopus
  40. H. Okamoto and N. Kamatani, “A CCR-5 antagonist inhibits the development of adjuvant arthritis in rats,” Rheumatology, vol. 45, no. 2, pp. 230–232, 2006. View at Publisher · View at Google Scholar · View at Scopus
  41. B. Moser and P. Loetscher, “Lymphocyte traffic control by chemokines,” Nature Immunology, vol. 2, no. 2, pp. 123–128, 2001. View at Publisher · View at Google Scholar · View at Scopus
  42. M. Baggiolini, A. Walz, and S. L. Kunkel, “Neutrophil-activating peptide-1/interleukin 8, a novel cytokine that activates neutrophils,” Journal of Clinical Investigation, vol. 84, no. 4, pp. 1045–1049, 1989. View at Google Scholar · View at Scopus
  43. E. Trysberg, K. Nylen, L. E. Rosengren, and A. Tarkowski, “Neuronal and astrocytic damage in systemic lupus erythematosus patients with central nervous system involvement,” Arthritis and Rheumatism, vol. 48, no. 10, pp. 2881–2887, 2003. View at Publisher · View at Google Scholar · View at Scopus
  44. S. K. Bromley, T. R. Mempel, and A. D. Luster, “Orchestrating the orchestrators: chemokines in control of T cell traffic,” Nature Immunology, vol. 9, no. 9, pp. 970–980, 2008. View at Publisher · View at Google Scholar · View at Scopus
  45. N. Yajima, T. Kasama, T. Isozaki et al., “Elevated levels of soluble fractalkine in active systemic lupus erythematosus: potential involvement in neuropsychiatric manifestations,” Arthritis and Rheumatism, vol. 52, no. 6, pp. 1670–1675, 2005. View at Publisher · View at Google Scholar · View at Scopus
  46. E. Sato, N. Iikuni, T. Yoshio, S. Minota, N. Kamatani, and H. Okamoto, “Soluble fractalkine in the cerebrospinal fluid of patients with neuropsychiatric lupus,” Annals of the Rheumatic Diseases, vol. 65, no. 9, pp. 1257–1259, 2006. View at Publisher · View at Google Scholar · View at Scopus
  47. L. Stievano, E. Piovan, and A. Amadori, “C and CX3C chemokines: cell sources and physiopathological implications,” Critical Reviews in Immunology, vol. 24, no. 3, pp. 205–228, 2004. View at Publisher · View at Google Scholar · View at Scopus
  48. G. Murphy, N. Caplice, and M. Molloy, “Fractalkine in rheumatoid arthritis: a review to date,” Rheumatology, vol. 47, no. 10, pp. 1446–1451, 2008. View at Publisher · View at Google Scholar · View at Scopus
  49. W. Sato, T. Aranami, and T. Yamamura, “Cutting edge: human Th17 cells are identified as bearing CCR2+CCR5 phenotype,” Journal of Immunology, vol. 178, no. 12, pp. 7525–7529, 2007. View at Google Scholar · View at Scopus
  50. H. Okamoto, T. P. Cujec, H. Yamanaka, and N. Kamatani, “Molecular aspects of rheumatoid arthritis: role of transcription factors,” FEBS Journal, vol. 275, no. 18, pp. 4463–4470, 2008. View at Publisher · View at Google Scholar · View at Scopus